Clinical trials: Staphylococcal Infections
Staphylococcal Infections
Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates
The main objective will be to test the safety of two intravenous infusions of Altastaph, a human immunoglobulin product. The study will also test the ability of Altastaph to protect against S. aureus infection.
- Trial name
- NCT00066989
- Testing
- Staphylococcus aureus Immune Globulin (Human) 5%
- Volunteers
- 200 people
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcal Infections
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus aureus (MRSA) infection disease. The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from…
- Trial name
- NCT00666276
- Testing
- linezolid (Zyvox)
- Volunteers
- 1,004 people
- Sponsor
- Pfizer
Staphylococcal Infections, Kidney Failure, Chronic
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
Two part study testing the effectiveness and safety of StaphVAX vaccine in chronic hemodialysis patients against infection by Staphylococcus aureus.
- Trial name
- NCT00071214
- Testing
- S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine
- Volunteers
- 3,600 people
- Sponsor
- Nabi Biopharmaceuticals
Impetigo
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
- Trial name
- NCT03429595
- Testing
- ATx201, ATx201 GEL Vehicle
- Where
- 16 sites in South Africa
- Volunteers
- 210 people
- Sponsor
- UNION therapeutics
Staphylococcal Infections, Surgical Site Infection
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
This study looks at the difference between XF-73 and placebo in reducing the carriage of a bacteria S. aureus in the nose before, during and after heart surgery.
- Trial name
- NCT03915470
- Testing
- XF-73
- Where
- 21 sites in United States, Georgia and 1 more
- Volunteers
- 124 people
- Sponsor
- Destiny Pharma Plc
Skin Infection, Bacterial Infection
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections.
- Trial name
- NCT02052388
- Testing
- Daptomycin, Brilacidin
- Where
- 4 sites in United States
- Volunteers
- 215 people
- Sponsor
- Cellceutix Corporation
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Surgical Site Infections, Infections
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada
This is a Phase 4 multi-center, group-randomized, crossover trial to compare nasal antimicrobial photodisinfection therapy (aPDT) with standard of care for prevention of surgical site infections in patients undergoing major…
- Conditions
- Surgical Site Infections, Infections, Surgical Wound Infections, Anti-Infective Agents
- Trial name
- LANTERN (NCT07189858)
- Testing
- Nasal antimicrobial photodisinfection therapy
- Where
- 4 sites in Canada
- Volunteers
- 401 people
- Sponsor
- Ondine Biomedical Inc.
Infectious Skin Diseases, Bacterial Skin Diseases
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections
- Conditions
- Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections
- Trial name
- NCT00646958
- Testing
- Radezolid, Linezolid
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Melinta Therapeutics, Inc.
Staphylococcal Infections
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag).
- Trial name
- NCT01364571
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 16 sites in United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER II (NCT01468233)
- Testing
- adalimumab
- Volunteers
- 326 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Staphylococcal Sepsis
Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants
The purpose of this Phase 1 study is to evaluate the safety and pharmacokinetics of BSYX-A110 in a small number of healthy adult volunteers.
- Trial name
- NCT00636285
- Testing
- BSYX-A110
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Secondarily Infected Traumatic Lesions (SITL), Impetigo
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic…
- Trial name
- NCT00758862
- Testing
- 2% TD1414 Cream
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- LEO Pharma
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Impetigo
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
Impetigo is a common, highly infectious skin disease caused by bacterial infection and characterized by crusting skin lesions. It is most common in children, particularly children in unhealthy living conditions.
- Trial name
- NCT01171326
- Testing
- Topical Minocycline Foam FXFM244
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Vyne Therapeutics Inc.
Staphylococcal Infections, Chronic Kidney Failure
Evaluation of Manufacturing Lot of StaphVAX
This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine.
- Trial name
- NCT00211900
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bacteremia
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects…
- Trial name
- NCT02208063
- Testing
- Telavancin, Vancomycin, Daptomycin
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Cumberland Pharmaceuticals
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS1 (NCT00091819)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 862 people
- Sponsor
- Cumberland Pharmaceuticals
Atopic Dermatitis
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs.
- Trial name
- NCT04192513
- Testing
- J. lividum
- Where
- Dominican Republic
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.